National Coverage Analysis (NCA) Tracking Sheet for Autologous Cellular Immunotherapy Treatment of Metastatic Prostate Cancer
<p>
BIO is concerned about CMS’ decision to open an NCA on a recently-approved therapy because it could establish a precedent that affects Medicare patient access to a wide range of innovative drug and biological therapies on a national basis.</p>
BIO is concerned about CMS’ decision to open an NCA on a recently-approved therapy because it could establish a precedent that affects Medicare patient access to a wide range of innovative drug and biological therapies on a national basis.
